Does tirzepatide (Mounjaro/Zepbound) cause hair loss? It is a question increasingly raised by patients and clinicians as use of this dual GIP and GLP-1 receptor agonist grows across the UK. Alopecia is listed as an adverse reaction in the Zepbound Summary of Product Characteristics for weight management, but is absent from the Mounjaro SmPC for type 2 diabetes. Crucially, current evidence suggests hair shedding is more likely driven by the physiological stress of rapid weight loss — a condition known as telogen effluvium — than by a direct pharmacological effect of tirzepatide on hair follicles.

Can Mounjaro or Zepbound Cause Hair Loss?

Alopecia is listed in the Zepbound SmPC for weight management but not in the Mounjaro SmPC for type 2 diabetes; hair shedding is attributed to rapid weight loss causing telogen effluvium rather than a direct drug effect on hair follicles.

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist available in the UK under two brand names: Mounjaro, licensed by the MHRA for the management of type 2 diabetes, and Zepbound, licensed for chronic weight management in adults with obesity or overweight with at least one weight-related health condition. As use of both products has grown, some patients and clinicians have raised questions about whether tirzepatide can cause hair loss.

The answer depends on which indication is being considered. Alopecia is listed as an adverse reaction in the UK Summary of Product Characteristics (SmPC) for Zepbound (weight management), where it is considered to be associated with the significant weight loss the medicine produces. It is not listed as an adverse reaction in the Mounjaro (type 2 diabetes) SmPC. Patients and prescribers should consult the relevant UK SmPC, available via the Electronic Medicines Compendium (EMC), for the most current and complete adverse reaction information.

Importantly, there is no established direct pharmacological link between tirzepatide itself and hair follicle damage. The hair shedding reported by some patients is more likely attributable to the physiological stress of rapid caloric restriction and substantial weight reduction — a well-recognised phenomenon known as telogen effluvium — rather than a direct drug effect on hair follicles. Evidence for this distinction remains limited, and patients should be informed of this uncertainty.

Patients should be reassured that hair shedding, if it occurs, is generally temporary and reversible. Nevertheless, any new or worsening hair loss during treatment warrants discussion with a GP or prescriber to rule out other contributing causes, such as nutritional deficiencies or thyroid dysfunction. Suspected side effects can be reported to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk.

How GLP-1 and GIP Receptor Agonists May Affect Hair Growth

Hair shedding associated with tirzepatide and semaglutide is thought to result from telogen effluvium triggered by rapid weight loss and caloric restriction, not from direct GLP-1 or GIP receptor agonism disrupting the hair growth cycle.

Tirzepatide belongs to the broader class of incretin-based therapies. Semaglutide (marketed as Ozempic for type 2 diabetes and Wegovy for weight management) is a GLP-1 receptor agonist that has similarly been associated with reports of hair loss. Although the two agents have different mechanisms — tirzepatide acts on both GIP and GLP-1 receptors, whilst semaglutide acts on GLP-1 receptors alone — understanding the proposed mechanisms is relevant to both, with the important caveat that evidence for a direct drug class effect on hair follicles is currently lacking.

These medicines work by mimicking incretin hormones, stimulating insulin secretion in a glucose-dependent manner, suppressing glucagon, slowing gastric emptying, and reducing appetite. The resulting caloric deficit and weight loss — which can be substantial over the course of treatment, as demonstrated in the SURMOUNT and STEP trial programmes — can place considerable physiological stress on the body. This metabolic stress is thought to be the primary driver of hair shedding, rather than any direct action of the drug on hair follicles.

Telogen effluvium, the most likely mechanism, occurs when a physiological stressor — such as rapid weight loss, surgery, illness, or nutritional deficiency — causes a disproportionate number of hair follicles to enter the resting (telogen) phase simultaneously. Shedding typically becomes noticeable two to four months after the triggering event and may last for several months before spontaneous recovery. Current evidence does not demonstrate that GLP-1 or GIP receptor agonism directly disrupts the hair growth cycle at a molecular level, though robust mechanistic studies are limited. Nutritional factors, particularly inadequate protein intake during caloric restriction, may compound the problem and are an important consideration during treatment. The NHS and the British Association of Dermatologists (BAD) provide accessible patient information on telogen effluvium and its typical course.

What the Clinical Evidence Says

In the SURMOUNT trials, alopecia occurred more frequently with tirzepatide than placebo and was more common in women; the EMA and UK SmPC attribute this to weight loss rather than a direct drug effect.

Clinical evidence specifically examining hair loss as an adverse effect of tirzepatide is still emerging. In the SURMOUNT obesity trial programme — the pivotal studies evaluating tirzepatide for weight management — alopecia events occurred more frequently in participants receiving tirzepatide than in those receiving placebo, and were more commonly reported in women. The EMA European Public Assessment Report (EPAR) for Zepbound and the UK SmPC reflect this finding, noting that alopecia is considered to be associated with weight loss rather than a direct drug effect. Patients and clinicians seeking precise incidence figures should consult the Zepbound SmPC and the primary SURMOUNT-1 and SURMOUNT-2 publications (Jastreboff et al., NEJM, 2022; Frías et al., NEJM, 2021).

Post-marketing surveillance and real-world data have begun to surface reports of hair thinning among users of GLP-1 receptor agonists more broadly. The MHRA continues to monitor the safety profile of tirzepatide in the UK through the Yellow Card Scheme; patients and healthcare professionals are encouraged to report any suspected adverse reactions at yellowcard.mhra.gov.uk. Spontaneous reporting systems such as the US FDA Adverse Event Reporting System (FAERS) can generate signals but cannot establish causality and should be interpreted with caution.

Observational data suggest that hair loss rates among individuals using GLP-1 receptor agonists are broadly consistent with rates expected in individuals undergoing equivalent degrees of weight loss through other means, such as bariatric surgery. This supports the hypothesis that rapid weight reduction — rather than the medication itself — is the primary causative factor. However, robust, prospective, controlled data specifically addressing tirzepatide and hair loss remain limited, and patients should be informed of this uncertainty when discussing treatment expectations.

Managing Hair Loss During Treatment

Management focuses on optimising protein and micronutrient intake, avoiding aggressive hair treatments, and considering a more gradual rate of weight loss; telogen effluvium is typically self-limiting, with regrowth beginning within three to six months.

For patients experiencing hair shedding whilst taking Mounjaro or Zepbound, a number of practical strategies may help to minimise the impact and support hair recovery. Management should be approached holistically, addressing nutritional adequacy, general wellbeing, and any identifiable underlying causes.

Key management strategies include:

• Optimise protein intake: Adequate dietary protein is important for hair follicle health. Protein requirements during significant weight loss should be individualised by a clinician or registered dietitian, as needs vary according to body weight, rate of weight loss, and medical history. Higher protein intakes may not be appropriate for individuals with chronic kidney disease (CKD), hepatic disease, or certain other conditions; patients should seek personalised advice rather than applying a fixed target. The British Dietetic Association (BDA) provides resources on nutrition during weight management.

• Address micronutrient deficiencies: Deficiencies in iron (ferritin), vitamin D, and zinc have been associated with diffuse hair shedding. A GP can arrange initial blood tests — typically a full blood count (FBC), ferritin (with C-reactive protein if inflammation is suspected), and thyroid-stimulating hormone (TSH) — and may consider vitamin D or zinc testing if clinically indicated. Routine testing for biotin is not standard practice in UK primary care for diffuse hair loss. Importantly, the MHRA has issued a Drug Safety Update warning that biotin (vitamin B7) supplementation can interfere with a range of laboratory immunoassays, potentially causing false results; patients should inform their healthcare team if they are taking biotin supplements.

• Avoid aggressive hair treatments: During periods of shedding, minimising heat styling, chemical treatments, and tight hairstyles can reduce additional mechanical stress on fragile hair.

• Consider the rate of weight loss: Where clinically appropriate and agreed with a prescriber, a more gradual rate of weight reduction may reduce the physiological stress that triggers telogen effluvium.

• Scalp care: Gentle shampoos and scalp massage are sometimes suggested as supportive measures, but evidence for specific topical interventions in telogen effluvium is limited; these should be regarded as optional comfort measures rather than treatments.

• Dietetic input: If caloric restriction is substantial or hair shedding is significant, referral to a registered dietitian should be considered to ensure nutritional adequacy.

Patients should be reassured that telogen effluvium is typically self-limiting. Hair regrowth usually begins within three to six months of the triggering stressor resolving or stabilising. Maintaining open communication with a healthcare professional throughout treatment is essential to ensure that any underlying causes are identified and addressed promptly.

When to Speak to Your GP or Prescriber

Patients should seek GP advice for sudden or severe shedding, patchy hair loss, scalp symptoms, systemic symptoms, or persistent shedding beyond six months; a GP can arrange blood tests and refer to NHS dermatology if needed.

Whilst mild, temporary hair shedding during significant weight loss is generally not a cause for alarm, there are circumstances in which patients should seek prompt medical advice. Not all hair loss is attributable to telogen effluvium, and a thorough clinical assessment is important to exclude other underlying conditions.

Patients should contact their GP or prescriber if they notice:

• Sudden or severe hair loss that appears disproportionate to the degree of weight lost

• Patchy hair loss or bald spots, which may suggest alopecia areata or another dermatological condition

• Scalp pain, redness, scaling, pustules, or broken hairs, which may indicate scarring alopecia or tinea capitis and warrant prompt assessment

• Hair loss accompanied by other symptoms, such as fatigue, cold intolerance, unexpected weight changes, or skin changes — which may indicate thyroid dysfunction or another systemic condition

• Persistent shedding that continues beyond six months without signs of regrowth

• Significant distress related to hair loss, which may warrant referral for specialist assessment

A GP can arrange relevant initial investigations, including a full blood count (FBC), ferritin (with CRP if indicated), and thyroid function tests (TSH), with further tests guided by clinical history. Where the diagnosis is uncertain, hair loss is persistent, or scarring alopecia is suspected, referral to NHS dermatology is the appropriate pathway. The Primary Care Dermatology Society (PCDS) and NICE Clinical Knowledge Summaries provide guidance on investigation and referral for diffuse hair loss in primary care.

Patients should never stop taking Mounjaro or Zepbound without first discussing this with their prescriber. The decision to continue, adjust, or discontinue treatment should always be made collaboratively, weighing the benefits of glycaemic control or weight management against any side effects experienced. NICE guidance emphasises shared decision-making in the management of obesity and type 2 diabetes, and patient concerns about quality of life — including hair loss — are a valid and important part of that conversation.

Suspected adverse reactions to tirzepatide should be reported to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk.

Frequently Asked Questions